Cyclooxygenase-2 expression associated with severity of PanIN lesions: A possible link between chronic pancreatitis and pancreatic cancer

Pancreatology

Volumn 5, Issue 4-5, 2005, Pages 361-369

  Albazaz, R ^a   Verbeke, C S ^b   Rahman, S H ^a   McMahon, M J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chronic pancreatitis; Cyclooxygenase 2; Pancreatic adenocarcinoma; Pancreatic intraepithelial neoplasia

Indexed keywords

BIOLOGICAL MARKER; CHLORDANE; COLLAGEN; CYCLOOXYGENASE 2; ISOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LOCALIZATION; FEMALE; FIBROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; PANCREAS CANCER; PANCREAS INTRAEPITHELIUM NEOPLASM; PANCREAS TUMOR; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STELLATE CELL; TISSUE DISTRIBUTION; TISSUE SECTION;

EID: 23844478990     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000086536     Document Type: Article

References (39)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Almoguera C, Shibata D, Forrester K, et al: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
3. Rozenblum E, Schutte M, Goggins M, et al: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-1734.
4. Hruban RH, Adsay NV, Albores-Saavedra J, et al: Pancreatic intraepithelial neoplasia. A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-586.
5. Hruban RH, Wilentz RE, Kern SE: Genetic progression in the pancreatic ducts. Am J Pathol 2000;156:1821-1825.
6. Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433-1437.
7. Farrow B, Evers BM: Inflammation and the development of pancreatic cancer. Surg Oncol 2002;10:153-169.
8. Dannenberg AJ, Altorki NK, Boyle JO, et al: Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-551.
9. Grover JK, Yadav S, Vats V, et al: Cyclo-oxygenase 2 inhibitors: Emerging roles in the gut. Int J Colorectal Dis 2003;18:279-291.
10. Langman MJS, Cheng KK, Gilman EA, et al: Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ 2000;320:1642-1646.
11. Schernhammer ES, Kang JH, Chan AT, et al: A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 2004;96:22-28.
12. Anderson KE, Johnson TW, Lazovich D, et al: Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002;94:1168-1171.
13. Ding XZ, Hennig R, Adrian TE: Lipoxygenase and cyclooxygenase metabolism: New insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer 2003;2:10-21.
14. Ding XZ, Tong WG, Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000;20:2625-2632.
15. Yip-Schneider MT, Wiesenauer CA, Schmidt CM: Inhibition of the phosphatidylinositol 3′-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastrointest Surg 2003;7:354-363.
16. Tong WG, Ding XZ, Witt RC, et al: Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 2002;1:929-935.
17. Takahashi M, Furukawa F, Toyoda K, et al: Effect of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990;11:393-395.
18. Sobin LH, Wittekind C (eds): UICC: TNM Classification of Malignant Tumours, ed 5. New York, Wiley, 1997.
19. Chapple KS, Scott N, Guillou PJ, et al: Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol 2002;198:435-441.
20. Hull MA, Thomson JL, Hawkey CJ: Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 1999;45:529-536.
21. Pablos JL, Santiago B, Carreira PE, et al: Cyclooxygenase-1 and -2 are expressed by human T cells. Clin Exp Immunol 1999;115:86-90.
22. Weiderpass E, Partanen T, Kaaks R, et al: Occurrence, trends and environment etiology of pancreatic cancer. Scand J Work Environ Health 1998;24:161-164.
23. Koliopanos A, Friess H, Kleef J, et al: Cyclooxygenase-2 expression in chronic pancreatitis: Correlation with stage of the disease and diabetes mellitus. Digestion 2001;64:240-247.
24. Okami J, Yamamoto H, Fujiwara Y, et al: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-2024.
25. Tucker ON, Dannenberg AJ, Yang EK, et al: Cyclooxygenase expression is upregulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
26. Koshiba T, Hosotani R, Miyamoto Y, et al: Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999;26:69-76.
27. Molina MA, Sitja-Arnau M, Lemoine MG, et al: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-4362.
28. Yip-Schneider MT, Bernard DS, Billings SD, et al: Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-146.
29. Niijima M, Yamaguchi T, Ishihara T, et al: Immunohistochemical analysis and in situ hybridisation of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 2002;94:1565-1573.
30. Robertson RP: Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 1998;47:1379-1383.
31. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge G, Be HG: Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002;25;26-30.
32. Merati K, Siadaty MS, Andea A, et al: Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001;24:447-452.
33. Zabel-Langhennig A, Holler B, Engeland K, et al: Cyclooxygenase-2 transcription is stimulated and amylase secretion is inhibited in pancreatic acinar cells after induction of acute pancreatitis. Biochem Biophys Res Commun 1999;265:545-549.
34. 2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide. J Physiol Pharmacol 2001;52:107-126.
35. Maitra A, Ashfaq R, Gunn CR, et al: Cyclooxygenase-2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia. An immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002;118:194-201.
36. Kokawa A, Kondo H, Gotoda T, et al: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-338.
37. Madaan S, Abel PD, Chaudhary KS, et al: Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. BJU Int 2000;86:736-741.
38. Agoff SN, Crispin DA, Bronner MP, et al: Neoplasms of the ampulla of Vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol 2001:14;139-146.
39. Rosty C, Geradts J, Sato N, Wilentz RE, Roberts H, Sohn T, Cameron JL, Yeo CJ, Hruban RH, Goggins M: p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. Am J Surg Pathol 2003;27:1495-1501.